Raynaud’s Syndrome

Top Story

Direct-to-consumer genetic testing not ready for prime time in rheumatology

Direct-to-consumer genetic testing not ready for prime time in rheumatology
January 18, 2019
In the Journals

Few rheumatic adverse events from immune checkpoint inhibitors require discontinuation

November 15, 2018
Researchers found that the most prevalent adverse effect linked to immune checkpoint inhibitors was inflammatory arthritis, and although most patients received long…
In the Journals

On-demand sildenafil not superior to placebo for Raynaud's syndrome

October 29, 2018
Despite a high probability that on-demand sildenafil is superior to placebo in the treatment of Raynaud’s syndrome, aggregate observed findings failed to…
In the Journals

Wearable devices linked to increased activity in rheumatic diseases

October 11, 2018
The use of wearable devices that track movement is effective in significantly increasing the amount of and time spent performing moderate to vigorous physical activity…
More Headlines »

Rheum360: Focus on Biosimilars

This activity is supported by an independent medical education grant from Sandoz Inc., a Novartis Division.

Chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, psoriatic arthritis, vasculitis, and axial…
More »
Meeting News

AVERT-2 fails to meet primary endpoint, but data advances the field for RA

November 6, 2018
More »

Ace the Case: A 71-Year-Old Woman With a 3-Month History of Right-Sided Headaches, Bilateral Shoulder Weakness, and Generalized Malaise

There is no commercial support for this activity.

This educational activity will utilize a case study to discuss the diagnosis and management of a 71-year-old woman with…
More »